Trial Profile
A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Feb 2024
Price :
$35
*
At a glance
- Drugs Atropine (Primary)
- Indications Myopia
- Focus Registrational; Therapeutic Use
- Acronyms CHAMP
- Sponsors Nevakar; Vyluma
- 11 Oct 2023 Status changed from active, no longer recruiting to completed, according to a Vyluma media release.
- 11 Oct 2023 Results presented in a Vyluma media release.
- 08 Oct 2023 This has been completed in Netherlands (global end date: 2023-07-29), according to a European Clinical Trials Database.